Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Qtron Investments LLC

Key Points

• Qtron Investments LLC increased its stake in Regeneron Pharmaceuticals by 37.5%, owning nearly $1.23 million worth of shares after acquiring additional stock during the first quarter.
• A variety of institutional investors, including Vanguard Group and Goldman Sachs, have also boosted their holdings in Regeneron, with institutional ownership now at 83.31% of the company's stock.
• Regeneron reported a 12.89 EPS for the last quarter, beating analysts' expectations and reflecting a 3.6% year-over-year revenue increase. The company has announced a quarterly dividend of $0.88 per share.

Qtron Investments LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,945 shares of the biopharmaceutical company's stock after acquiring an additional 530 shares during the quarter. Qtron Investments LLC's holdings in Regeneron Pharmaceuticals were worth $1,234,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after buying an additional 174,056 shares during the period. Northern Trust Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock valued at $751,386,000 after buying an additional 136,184 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after buying an additional 226,952 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a report on Friday, August 1st. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. Finally, Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $890.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $838.00.

Regeneron Pharmaceuticals Trading Up 2.6%

REGN opened at $580.41 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The stock has a market capitalization of $61.52 billion, a PE ratio of 14.63, a P/E/G ratio of 1.93 and a beta of 0.33. The business's 50 day moving average price is $544.21 and its 200 day moving average price is $594.28. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the firm posted $11.56 earnings per share. The firm's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.